Psychedelic drug company Mind Medicine Inc. (MindMed) (NASDAQ: MNMD) published its 2025 Investor Presentation this week with ...

ByInvesting.com • 14 Dec 2023 Mind Medicine Reports Positive Topline Results from Phase 2b Trial of MM-120 Mind Medicine (MindMed) Inc. (MNMD) today announced positive topline results from its Phase ...

Mind Medicine (MNMD) (ISIN: CA60255C8850)股票专题，提供今日Mind Medicine(MNMD) (ISIN: CA60255C8850)股票最新股价查询，实时市场行情，走势图表，及Mind Medicine Inc(MNMD) (ISIN: CA60255C8850)股票的专业技术分析，投资者论坛，历史交易数据，最新消息和未来价格预测。

Chardan Capital Markets has recently initiated Mind Medicine (MindMed) Inc (MNMD) stock to Buy rating, as announced on December 20, 2024, according to Finviz. Earlier, on October 14, 2024, Leerink ...

Lysergic acid diethylamide is under clinical development by Mind Medicine MindMed and currently in Phase II for Major Depressive Disorder. According to GlobalData, Phase II drugs for Major Depressive ...

Lysergic acid diethylamide is under clinical development by Mind Medicine MindMed and currently in Phase II for Generalized Anxiety Disorder (GAD). According to GlobalData, Phase II drugs for ...

Mind Medicine (MindMed) MNMD is developing its lead pipeline candidate, MM120, an orally disintegrating tablet (ODT) and a pharmaceutically optimized form of lysergide D-tartrate (LSD), for the ...

In a recent transaction, Robert Barrow, the Chief Executive Officer of Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), sold a total of 15,659 common shares of the company. The sale,... Mind Medicine ...

Mind Medicine Inc., also known as MindMed, is a New York-based psychedelic medicine biotech company that develops psychedelic-inspired medicines known as psychoplastogens and therapies to address ...